Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SPPH has been having a massive new release party the past couple months..more is coming!
SPPH has great volume today so far too!
definitely a great buying op here. no doubts about that
this little dip isn't anything to worry about...i've seen SPPH rebound from a much harder dip. buying will come in near EOD!
All recent PRs from SPPH
http://www.spencerpharmaceutical.com/index.php?pg=quotes&cat=ir
All recent PRs from SPPH
http://www.spencerpharmaceutical.com/index.php?pg=quotes&cat=ir
SPPH INFO
Spencer Pharmaceuticals is a newly formed public company specializing in the identification of new drug delivery applications. A global player in the biopharmaceutical market, Spencer has forged relationships with two highly respected laboratories located in Universities throughout the world. Our focus is on newly patented formulation of existing drugs from the incubation to the developmental stages or newly synthesized drugs able to cross the blood-brain barrier. Our partners are experienced researchers providing the Company years of research, now ready for the drug-development status.
SPPH INFO
Spencer Pharmaceuticals is a newly formed public company specializing in the identification of new drug delivery applications. A global player in the biopharmaceutical market, Spencer has forged relationships with two highly respected laboratories located in Universities throughout the world. Our focus is on newly patented formulation of existing drugs from the incubation to the developmental stages or newly synthesized drugs able to cross the blood-brain barrier. Our partners are experienced researchers providing the Company years of research, now ready for the drug-development status.
Spencer Pharmaceuticals is a newly formed public company specializing in the identification of new drug delivery applications. A global player in the biopharmaceutical market, Spencer has forged relationships with two highly respected laboratories located in Universities throughout the world. Our focus is on newly patented formulation of existing drugs from the incubation to the developmental stages or newly synthesized drugs able to cross the blood-brain barrier. Our partners are experienced researchers providing the Company years of research, now ready for the drug-development status.
should be seeing some more of those this week...now let the buying start!
already close to 50k today..we should be able to see 175-200k !
SPPH NEWS
Spencer Pharmaceutical Partners With National Pharmaceutical in the Development of Central Nervous System Disease Treatments
marketwire
*
Share
*
retweet
* Email
* Print
*
Companies:
o Spencer Pharmaceutical Inc.
Related Quotes
Symbol Price Change
SPPH.PK 0.29 -0.01
Chart for EMERGENSYS CORP
{"s" : "spph.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""}
Press Release Source: Spencer Pharmaceutical Inc. On Monday November 1, 2010, 8:30 am EDT
BOSTON, MA--(Marketwire - 11/01/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today that it has signed a preliminary cooperative development agreement with National Pharmaceutical Corp.
According to the agreement, Spencer and National will develop central nervous disease treatments in the areas of Alzheimer and Parkinson using Spencer's drug delivery as the primary platform. The preliminary agreement calls for a share swap of 20 million restricted shares. The final terms and conditions of the transaction will be determined in a definitive agreement. No assurances can be provided that a definitive agreement will be executed. Execution of a definitive agreement is subject to, among other things, confirming due diligence by Spencer, and other conditions and approvals by both companies' management, board of directors and shareholders, as appropriate.
"We are pleased to be working with another group in the development of treatments for CNS related diseases. As many current patented drugs are becoming free of royalties, our technology would extend the patent of treatments in Alzeimers and Parkinsons," said Dr. Arella, President of Spencer Pharmaceutical Inc. "CNS disease treatments are one of the areas where our technology can be of use in extending the life of the patents, but we are also investigating many other areas such as anti-psychotic and anti-depressor drugs," further added Dr. Arella.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
Important Information About Forward-Looking Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above. In addition, such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the Company's website does not constitute a part of this release.
Contact:
Contact:
Dr. Max Arella
President
Spencer Pharmaceutical Inc.
Tel. 1+(617) 973-5017
SPPH NEWS
Spencer Pharmaceutical Partners With National Pharmaceutical in the Development of Central Nervous System Disease Treatments
marketwire
*
Share
*
retweet
* Email
* Print
*
Companies:
o Spencer Pharmaceutical Inc.
Related Quotes
Symbol Price Change
SPPH.PK 0.29 -0.01
Chart for EMERGENSYS CORP
{"s" : "spph.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""}
Press Release Source: Spencer Pharmaceutical Inc. On Monday November 1, 2010, 8:30 am EDT
BOSTON, MA--(Marketwire - 11/01/10) - Spencer Pharmaceutical Inc. (Pinksheets:SPPH - News) announced today that it has signed a preliminary cooperative development agreement with National Pharmaceutical Corp.
According to the agreement, Spencer and National will develop central nervous disease treatments in the areas of Alzheimer and Parkinson using Spencer's drug delivery as the primary platform. The preliminary agreement calls for a share swap of 20 million restricted shares. The final terms and conditions of the transaction will be determined in a definitive agreement. No assurances can be provided that a definitive agreement will be executed. Execution of a definitive agreement is subject to, among other things, confirming due diligence by Spencer, and other conditions and approvals by both companies' management, board of directors and shareholders, as appropriate.
"We are pleased to be working with another group in the development of treatments for CNS related diseases. As many current patented drugs are becoming free of royalties, our technology would extend the patent of treatments in Alzeimers and Parkinsons," said Dr. Arella, President of Spencer Pharmaceutical Inc. "CNS disease treatments are one of the areas where our technology can be of use in extending the life of the patents, but we are also investigating many other areas such as anti-psychotic and anti-depressor drugs," further added Dr. Arella.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
Important Information About Forward-Looking Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above. In addition, such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the Company's website does not constitute a part of this release.
Contact:
Contact:
Dr. Max Arella
President
Spencer Pharmaceutical Inc.
Tel. 1+(617) 973-5017
we already know strong support at .30
tons of interest. massive buying this week
company is very reliable with news releases
going to see some good volume this week!
going to bounce nicely
PPS held that 50day MA...should see a nice bounce off of it this coming week
this past week showed a huge surge of buying and an massive increase in volume!
i think that is key in the pinksheet market, transparency...we have it here and company is continuing to show more and more of their cards
definitely will see some more news from the company in the coming weeks IMO!
easily can move back to even and even get some green while were at it!
SPPH has been great with providing shareholders with info! more and more keeps coming out! I love how the PR machine has been cranking this month!
another awesome day of volume so far! plenty more time to go! let's get to 250k!
SPPH INFO
Spencer Pharmaceuticals is a newly formed public company specializing in the identification of new drug delivery applications. A global player in the biopharmaceutical market, Spencer has forged relationships with two highly respected laboratories located in Universities throughout the world. Our focus is on newly patented formulation of existing drugs from the incubation to the developmental stages or newly synthesized drugs able to cross the blood-brain barrier. Our partners are experienced researchers providing the Company years of research, now ready for the drug-development status.
Check out all the recent SPPH news!
http://www.spencerpharmaceutical.com/index.php?pg=quotes&cat=ir
Check out all the recent SPPH news!
http://www.spencerpharmaceutical.com/index.php?pg=quotes&cat=ir
SPPH INFO
Spencer Pharmaceuticals is a newly formed public company specializing in the identification of new drug delivery applications. A global player in the biopharmaceutical market, Spencer has forged relationships with two highly respected laboratories located in Universities throughout the world. Our focus is on newly patented formulation of existing drugs from the incubation to the developmental stages or newly synthesized drugs able to cross the blood-brain barrier. Our partners are experienced researchers providing the Company years of research, now ready for the drug-development status.
float around 50 million i believe! tight float, easy movement!
SPPH NEWS (yesterday's)
Spencer Pharmaceutical Inc. Mandates Independent Laboratory to Validate Met4 Findings
marketwire
*
Share
*
retweet
* Email
* Print
*
Companies:
o Spencer Pharmaceutical Inc.
Related Quotes
Symbol Price Change
SPPH.PK 0.27 -0.06
Chart for EMERGENSYS CORP
{"s" : "spph.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""}
Press Release Source: Spencer Pharmaceutical Inc. On Thursday October 28, 2010, 2:22 pm EDT
BOSTON, MA--(Marketwire - 10/28/10) - (Pinksheets:SPPH - News) Spencer Pharmaceutical Inc. announced today that an independent laboratory has been mandated to validate the met4 findings.
According to the mandate, the independent laboratory will perform the animal testing to validate the release time and efficiency of the new Spencer met4 formulation.
"Management believes that the independent laboratory will significantly increase the visibility of Spencer. These tests are straightforward and can be accomplished over the next month or so," stated Dr. Max Arella, President of Spencer Pharmaceutical Inc. Furthermore, "Tests are not only necessary but may help us in adding value to future licensing deals and can potentially provide significant revenue stream for the company in the near and long term while creating significant share hold value."
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
Important Information
About Forward-Looking Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above. In addition, such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the Company's website does not constitute a part of this release.
Contact:
Contact:
Dr. Max Arella
President
Spencer Pharmaceutical Inc.
1+(617) 973-5017
SPPH NEWS (yesterday's)
Spencer Pharmaceutical Inc. Mandates Independent Laboratory to Validate Met4 Findings
marketwire
*
Share
*
retweet
* Email
* Print
*
Companies:
o Spencer Pharmaceutical Inc.
Related Quotes
Symbol Price Change
SPPH.PK 0.27 -0.06
Chart for EMERGENSYS CORP
{"s" : "spph.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""}
Press Release Source: Spencer Pharmaceutical Inc. On Thursday October 28, 2010, 2:22 pm EDT
BOSTON, MA--(Marketwire - 10/28/10) - (Pinksheets:SPPH - News) Spencer Pharmaceutical Inc. announced today that an independent laboratory has been mandated to validate the met4 findings.
According to the mandate, the independent laboratory will perform the animal testing to validate the release time and efficiency of the new Spencer met4 formulation.
"Management believes that the independent laboratory will significantly increase the visibility of Spencer. These tests are straightforward and can be accomplished over the next month or so," stated Dr. Max Arella, President of Spencer Pharmaceutical Inc. Furthermore, "Tests are not only necessary but may help us in adding value to future licensing deals and can potentially provide significant revenue stream for the company in the near and long term while creating significant share hold value."
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.
Important Information
About Forward-Looking Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above. In addition, such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the Company's website does not constitute a part of this release.
Contact:
Contact:
Dr. Max Arella
President
Spencer Pharmaceutical Inc.
1+(617) 973-5017
Dont forget this addition to the team!
http://finance.yahoo.com/news/Spencer-Pharmaceutical-Inc-iw-2271063474.html?x=0&.v=1
SCIENTIFIC ADVISORY BOARD
Le Tien Canh, PhD. - Associate Professor, university of Quebec in Montreal
Mr. Canh has graduated in different areas (M.Sc. in Biology, M.Sc. in Chemistry and Ph.D. in Biochemistry) with diversified experiences in the academic and industrial sectors, polyvalent researcher. Some of his previous professional position includes VP and Director Research Development for Biopharmaceutical companies.
He specializes in various domains such as pharmaceutics, biomedical, food, etc. He is the author of numerous PCT related to various novel biotechnologies, biomaterials and medicinal products. His actual researches aim to highlight innovative technologies for oral delivery of pharmaceutical drugs based on peptides or proteins.
Dr. Francis Marsais
Dr. Marsais has been the Head of the chemistry department at the INSA of Rouen for the past 6 years. His past managerial positions include the construction and management of the IRCOF (Research centre for fine organic chemistry) since 1997. Dr. Marsais has an extensive research experience in organometallic and heterocyclic chemistry – biochemistry. He wrote 35 thesis in his career and 125 papers including 4 patents (Guerbet, ICI, Igol, Isochem, Roquette, PCAS, Igol, Orgachim, UCB Pharma, Sanofi-Aventis, Servier, Valdepharm, Somet...).
Mircea Alexandru Mateescu, Ph.D., - Professor of Biochemistry, Université du Québec à Montréal
Research scientist and professor of biochemistry, with experience and major contributions in different science domains such as drug delivery (sustained and delayed release) and biochemical pharmacology (cardioprotection and neuromodulation). Inventor of several novel biomaterials with pharmaceutical and biomedical applications, and of new technologies in the field of preparative biochemistry and pharmaceutical formulations. His Current activities are aimed to introduce novel drug delivery approaches such as the challenging move from injectable to oral or other administration forms of drug, vaccines or bioactive agents.
“Laurea” in Chemistry (1987) awarded by Rome University
Visiting Professor: Université Paris XIII, University of Rome "La Sapienza"
Prize «J-A. Bombardier» ACFAS 1999 for Technological Innovation in Canada
Honorary certificate from “Ville de Montréal – Mayor Gerald Tremblay.
SPPH MANAGEMENT TEAM
President & CEO - Max Arella, Ph.D.
For the past twenty five years, Dr. Arella has acted as a private consultant advising clients and businesses with technological and scientific development, innovative technology transfer and commercial development from university bench top to commercial developments. He acted as the president of a privately held Biotech company that successfully achieved business deals.
From 1993 to 1998 , Dr. Arella was elected twice as chairman of the Virology Research Center of the Armand-Frappier Institute/University of Quebec (the "IAF") during which he held the responsibility of managing both the research and the teaching programs (M.Sc. and Ph.D). From 1984 to 1993 Dr. Arella was scholar, assistant professor and professor of Virology at IAF as well as adjunct professor at the School of Graduate Studies of the University of Montreal. He also served as president of the professor association from 1989 to 1992.His academic research is mainly based in the fields of molecular biology, fundamental aspects and applications of the double-stranded RNA virus, as well as amplification systems for the analysis of human and animal viruses, and cancer markers.
Throughout his career, he has written 76 scientific publications, 24 scientific reports for research contracts as well as 28 chapters in books and summaries of techniques. He has been invited to give 52 international conferences, has presented 206 scientific communications and has submitted 3 patents. Mr. Arella is fluent in English, French and Italian. He is also a member of the board of directors of an OTCBB company (Protokinetix) and served in many advisory boards of public traded companies during the past fifteen years.
things are looking up for next week. i keep saying, the company is not done yet issuing PRs, this has just started!